Roche offers up to $554M in biobucks to in-need Kronos for small-molecule discovery pact

Kronos Bio had a rough end to 2022 after having to toss away a late-stage acute myeloid leukemia asset. But 2023 is already looking a bit brighter thanks to a new small-molecule drug discovery pact with Roche’s Genentech.